MY190324A - Anti-pd-1 antibodies and compositions - Google Patents
Anti-pd-1 antibodies and compositionsInfo
- Publication number
- MY190324A MY190324A MYPI2018701111A MYPI2018701111A MY190324A MY 190324 A MY190324 A MY 190324A MY PI2018701111 A MYPI2018701111 A MY PI2018701111A MY PI2018701111 A MYPI2018701111 A MY PI2018701111A MY 190324 A MY190324 A MY 190324A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibodies
- compositions
- cancer
- activity
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236341P | 2015-10-02 | 2015-10-02 | |
| PCT/EP2016/073421 WO2017055547A1 (en) | 2015-10-02 | 2016-09-30 | Anti-pd-1 antibodies and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY190324A true MY190324A (en) | 2022-04-14 |
Family
ID=57042898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018701111A MY190324A (en) | 2015-10-02 | 2016-09-30 | Anti-pd-1 antibodies and compositions |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11034765B2 (enExample) |
| EP (2) | EP3368572B9 (enExample) |
| JP (1) | JP6875385B2 (enExample) |
| KR (1) | KR102897330B1 (enExample) |
| CN (1) | CN108290953B (enExample) |
| AU (1) | AU2016333517B2 (enExample) |
| CA (1) | CA3000564A1 (enExample) |
| CO (1) | CO2018003500A2 (enExample) |
| CY (1) | CY1125327T1 (enExample) |
| DK (1) | DK3368572T3 (enExample) |
| ES (1) | ES2924402T3 (enExample) |
| HR (1) | HRP20221041T1 (enExample) |
| HU (1) | HUE059788T2 (enExample) |
| IL (1) | IL258214B2 (enExample) |
| LT (1) | LT3368572T (enExample) |
| MX (1) | MX2018003936A (enExample) |
| MY (1) | MY190324A (enExample) |
| PE (1) | PE20181044A1 (enExample) |
| PL (1) | PL3368572T3 (enExample) |
| PT (1) | PT3368572T (enExample) |
| RS (1) | RS63490B1 (enExample) |
| RU (1) | RU2750675C1 (enExample) |
| SA (1) | SA518391262B1 (enExample) |
| SG (1) | SG10201912943RA (enExample) |
| SI (1) | SI3368572T1 (enExample) |
| TW (1) | TWI751981B (enExample) |
| WO (1) | WO2017055547A1 (enExample) |
| ZA (1) | ZA201801852B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240046641A (ko) | 2015-04-17 | 2024-04-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 조율가능한 친화성을 갖는 면역조절 단백질 |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| PL3334763T3 (pl) | 2015-08-11 | 2024-12-02 | WuXi Biologics Ireland Limited | Nowe przeciwciała anty-pd-1 |
| MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| WO2017058859A1 (en) | 2015-09-29 | 2017-04-06 | Celgene Corporation | Pd-1 binding proteins and methods of use thereof |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
| MA43551A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants du ligand icos et leurs utilisations |
| KR102764225B1 (ko) | 2016-04-15 | 2025-02-07 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| FI3515938T3 (fi) | 2016-09-21 | 2025-03-27 | Cstone Pharmaceuticals | Monoklonaallisia vasta-aineita ohjelmoituun kuolemaan (PD-1) |
| KR20190088480A (ko) | 2016-11-02 | 2019-07-26 | 조운스 테라퓨틱스, 인크. | Pd-1에 대한 항체 및 그의 용도 |
| CA3043141A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
| AU2017373945B2 (en) | 2016-12-07 | 2025-01-23 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2018133837A1 (en) | 2017-01-20 | 2018-07-26 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-1 antibodies and uses thereof |
| IL268781B2 (en) | 2017-03-16 | 2025-09-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| UA129904C2 (uk) | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| US11466084B2 (en) * | 2017-06-25 | 2022-10-11 | Systimmune, Inc. | Anti-PD-1 antibodies and methods of making and using thereof |
| KR20250052490A (ko) | 2017-08-01 | 2025-04-18 | 에이비 테라퓨틱스 인코퍼레이티드 | 이중특이적 항체 및 그의 용도 |
| KR101917854B1 (ko) * | 2017-08-24 | 2018-11-12 | 한국콜마주식회사 | 세포 수용체 결합능이 있는 펩티드를 포함하는 마이크로 캡슐 및 이를 포함하는 화장료 조성물 |
| US20200283500A1 (en) | 2017-10-18 | 2020-09-10 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| JP7366056B2 (ja) | 2018-04-18 | 2023-10-20 | ゼンコア インコーポレイテッド | ＩＬ－１５／ＩＬ－１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ－３抗原結合ドメインを含む、ＬＡＧ－３を標的とするヘテロ二量体融合タンパク質 |
| TWI851572B (zh) | 2018-04-18 | 2024-08-11 | 美商山可爾股份有限公司 | IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途 |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| IL278400B2 (en) | 2018-05-07 | 2024-03-01 | Genmab As | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| JP2021527714A (ja) | 2018-06-20 | 2021-10-14 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 抗ｐｄ−１抗体及びその使用 |
| WO2020018354A1 (en) * | 2018-07-19 | 2020-01-23 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
| CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| WO2020037206A1 (en) * | 2018-08-16 | 2020-02-20 | Musc Foundation For Research Development | Recombinant myxoma viruses and uses thereof |
| US11498955B2 (en) * | 2018-09-14 | 2022-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | SPD-1 variant# FC fusion proteins |
| PE20211055A1 (es) * | 2018-10-12 | 2021-06-07 | Xencor Inc | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3873941A4 (en) * | 2018-10-31 | 2022-07-27 | Merck Sharp & Dohme Corp. | ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| WO2020132646A1 (en) | 2018-12-20 | 2020-06-25 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| CN111349162A (zh) * | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | 人源化抗pd-1抗体及其用途 |
| CA3122526C (en) | 2018-12-21 | 2023-01-03 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| EP3917579A4 (en) | 2019-01-28 | 2023-03-29 | AB Therapeutics, Inc. | SPECIFIC ANTIBODIES AND USES THEREOF |
| AR118619A1 (es) | 2019-04-10 | 2021-10-20 | Bio Thera Solutions Ltd | Anticuerpos de unión a pd-1 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| CN115023439A (zh) * | 2019-09-06 | 2022-09-06 | 西福根有限公司 | 抗cd73抗体 |
| CN115916233A (zh) * | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| CN112915202B (zh) * | 2019-12-06 | 2025-08-01 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| RS66193B1 (sr) | 2020-05-26 | 2024-12-31 | Boehringer Ingelheim Int | Anti-pd-1 antitela |
| CN116323673A (zh) * | 2020-08-10 | 2023-06-23 | 整体分子公司 | 用于制备抗体文库和从其分离的抗体的方法和组合物 |
| US20230331848A1 (en) * | 2020-08-31 | 2023-10-19 | Biosion Inc. | Pd-1 binding antibodies and uses thereof |
| WO2022108931A2 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| US20240034796A1 (en) * | 2021-02-04 | 2024-02-01 | Genuv Inc. | Anti-pd-1 antibody and use thereof |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| CA3233771A1 (en) | 2021-10-04 | 2023-04-13 | Les Laboratoires Servier | Cancer therapy targeting nkg2a |
| JP2024536383A (ja) | 2021-10-06 | 2024-10-04 | ジェンマブ エー／エス | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| US20250340668A1 (en) | 2022-05-11 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
| TW202413412A (zh) | 2022-05-12 | 2024-04-01 | 丹麥商珍美寶股份有限公司 | 在組合療法中能夠結合到ｃｄ２７之結合劑 |
| CA3257348A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | INTERLEUKIN-2 PROPROTEINS AND THEIR USES |
| KR20250035049A (ko) | 2022-06-04 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-2 프로프로테인 및 이의 용도 |
| CN120051483A (zh) | 2022-08-18 | 2025-05-27 | 再生元制药公司 | 干扰素前蛋白及其用途 |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2024182540A2 (en) | 2023-02-28 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| WO2024226875A2 (en) * | 2023-04-28 | 2024-10-31 | Initial Therapeutics, Inc. | Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins of the myc proto-oncogene family of bhlh transcription factors |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| WO2025122614A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| US20250376524A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101498834B1 (ko) * | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| MX2009001204A (es) | 2006-08-17 | 2009-02-11 | Hoffmann La Roche | Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico. |
| BRPI0808171A2 (pt) | 2007-03-01 | 2014-08-05 | Symphogen As | Método para clonagem de anticorpos cognatos |
| AU2009287165A1 (en) | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2691112B1 (en) | 2011-03-31 | 2018-05-23 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
-
2016
- 2016-09-30 MX MX2018003936A patent/MX2018003936A/es unknown
- 2016-09-30 JP JP2018516765A patent/JP6875385B2/ja active Active
- 2016-09-30 RU RU2018115979A patent/RU2750675C1/ru active
- 2016-09-30 TW TW105131644A patent/TWI751981B/zh active
- 2016-09-30 SG SG10201912943RA patent/SG10201912943RA/en unknown
- 2016-09-30 CN CN201680069542.1A patent/CN108290953B/zh active Active
- 2016-09-30 ES ES16774691T patent/ES2924402T3/es active Active
- 2016-09-30 RS RS20220762A patent/RS63490B1/sr unknown
- 2016-09-30 HU HUE16774691A patent/HUE059788T2/hu unknown
- 2016-09-30 DK DK16774691.6T patent/DK3368572T3/da active
- 2016-09-30 LT LTEPPCT/EP2016/073421T patent/LT3368572T/lt unknown
- 2016-09-30 US US15/765,337 patent/US11034765B2/en active Active
- 2016-09-30 HR HRP20221041TT patent/HRP20221041T1/hr unknown
- 2016-09-30 EP EP16774691.6A patent/EP3368572B9/en active Active
- 2016-09-30 MY MYPI2018701111A patent/MY190324A/en unknown
- 2016-09-30 CA CA3000564A patent/CA3000564A1/en active Pending
- 2016-09-30 PT PT167746916T patent/PT3368572T/pt unknown
- 2016-09-30 PL PL16774691.6T patent/PL3368572T3/pl unknown
- 2016-09-30 WO PCT/EP2016/073421 patent/WO2017055547A1/en not_active Ceased
- 2016-09-30 PE PE2018000485A patent/PE20181044A1/es unknown
- 2016-09-30 IL IL258214A patent/IL258214B2/en unknown
- 2016-09-30 KR KR1020187011821A patent/KR102897330B1/ko active Active
- 2016-09-30 SI SI201631586T patent/SI3368572T1/sl unknown
- 2016-09-30 AU AU2016333517A patent/AU2016333517B2/en active Active
- 2016-09-30 EP EP22174837.9A patent/EP4105235A1/en not_active Withdrawn
-
2018
- 2018-03-20 ZA ZA2018/01852A patent/ZA201801852B/en unknown
- 2018-04-02 CO CONC2018/0003500A patent/CO2018003500A2/es unknown
- 2018-04-02 SA SA518391262A patent/SA518391262B1/ar unknown
-
2022
- 2022-07-05 CY CY20221100455T patent/CY1125327T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY190324A (en) | Anti-pd-1 antibodies and compositions | |
| PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
| PH12019500668A1 (en) | Anti-lag-3 antibodies and compositions | |
| PH12019502724A1 (en) | Compositions for modulating c9orf72 expression | |
| MY207784A (en) | Anti-cd73 antibodies | |
| GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| NZ728688A (en) | Anti-pd-1 antibodies | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| CA2971734C (en) | Anti-pd-1 antibodies | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
| GB2569488A (en) | PD-1 specific aptamers |